Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- Wills Eye
- Study ID
- NCT07855770
- Phase
- PHASE2/PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Retinal Detachment Rhegmatogenous
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intravitreal 100% C3F8 Injection — PROCEDUREPatients with Macula off Rhegmatogenous Retinal Detachment will receive an intravitreal injection of 100% C3F8 prior to undergoing surgical repair for their condition
- Pars plana vitrectomy or pars plana vitrectomy with scleral buckle — PROCEDUREPatients with RRD will undergo standard of care treatment of RRD with pars plana vitrectomy or pars plana vitrectomy with scleral buckle
Study Details
The purpose of this study is to evaluate whether a preoperative intraocular gas injection improves visual outcomes in patients with a macula-off rhegmatogenous retinal detachment (RRD). While current surgical therapies successfully reattach the retina, visual recovery can vary. This study will investigate if injecting a small amount of gas (0.3 cc of 100% C3F8) into the eye prior to standard surgery can decrease the duration of macular detachment, reduce retinal displacement, and ultimately result in better final visual acuity compared to the standard of care alone.
Key Dates
- First listed
- Oct 2, 2026
- Start date
- Sep 21, 2026
- Status verified
- Sep 2026
- Primary completion
- Sep 30, 2028
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 190 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Preoperative GasPatients in this group will be injected with 0.3 cc of 100% C3F8 gas prior to surgical repair of the retinal detachment.
- Active Comparator: Standard of CarePatients in this arm will receive standard of care treatment with Pars Plana Vitrectomy or Pars Plana vitrectomy with Scleral Buckle.
Primary Outcome Measure
Visual Acuity [ Time Frame: 6 months ]
Central Contacts
- Omar Masoud, MD4452133130
- Zainab Rustam, MD6674147808
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wilmer Eye Institute, Johns Hopkins Hospital | Baltimore | Maryland | 21287 | |
| Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 |